Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTiziana Life Sc Share News (TILS)

Share Price Information for Tiziana Life Sc (TILS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 81.00
Bid: 80.00
Ask: 82.00
Change: -1.00 (-1.22%)
Spread: 2.00 (2.50%)
Open: 86.50
High: 87.7274
Low: 80.00
Yest. Close: 82.00
TILS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Fri, 21st Aug 2020 09:34

(Alliance News) - Tiziana Life Sciences PLC on Friday said it has obtained a US patient for the use of Milciclib in combination with tyrosine kinase inhibitors as a treatment for hepatocellular carcinoma and other cancers.

Shares in Tiziana were up 4.7% at 164.40 pence in London in morning trading.

The patent, granted by the US Patent & Trademark Office, will be published September 1 as patent number 10,758,541. It has been granted to London-based biotechnology company Tiziana for Milciclib plus tyrosine kinase inhibitors like Sorafenib, Regorafenib, and Lenvatinib.

Hepatocellular carcinoma, a type of liver cancer, has multiple underlying mechanisms, and patients often become resistant to monotherapies of existing therapeutics. There is a need for combination drug treatment approaches that target different mechanisms.

Tiziana recent presented two posters on clinical evaluation of Milciclib at the American Society of Clinical Oncology 2020 event. This included a poster on a phase 2a clinical evaluation of the drug which indicated the treatment was well tolerated and "produced encouraging clinical activity in sorafenib-resistant patients".

The second poster was on the evaluation of Milciclib, combined with tyrosine kinase inhibitor Regorafenib, in liver transplant patients with hepatocellular carcinoma recurrence. The combination proved to be safe and produced a "promising clinical response".

Kunwar Shailubhai, Tiziana's chief executive & chief scientific officer, said: "Advanced cases of patients with [hepatocellular carcinoma] have limited therapeutic options because of the heterogeneity of the multiple mechanisms underlying the development of drug resistance and limited clinical responses. Thus, combination of drugs with different mechanism of actions are necessary to achieve superior clinical outcome.

"We are delighted that we now have this key patent on use of Milciclib in combination with other HCC drugs, including a [tyrosine kinase inhibitor]. Issuance of this patent strengthens our clinical strategy as we move forward with the combination of Milciclib and a TKI for the clinical evaluation of advanced cases of HCC as well as in patients with recurrent HCC after liver transplantation."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

TRADING UPDATES: Clipper Logistics, JD Sports ink letter of intent

TRADING UPDATES: Clipper Logistics, JD Sports ink letter of intent

13 Apr 21 21:56

IN BRIEF: Tiziana plans phase II trials for nasal Covid-19 treatment

IN BRIEF: Tiziana plans phase II trials for nasal Covid-19 treatment

30 Mar 21 20:34

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

5 Feb 21 12:28

Tiziana Surges As Nasal Therapy May Be Effective In New Virus Variants

Tiziana Surges As Nasal Therapy May Be Effective In New Virus Variants

2 Feb 21 11:35

IN BRIEF: Tiziana Files US Statement Over USD250 Million Of Securities

IN BRIEF: Tiziana Files US Statement Over USD250 Million Of Securities

27 Jan 21 14:22

UK EXECUTIVE CHANGE SUMMARY: Ex-Savills CEO To Be Tritax Big Box Chair

UK EXECUTIVE CHANGE SUMMARY: Ex-Savills CEO To Be Tritax Big Box Chair

13 Jan 21 16:21

UK EXECUTIVE CHANGE SUMMARY: Premier Oil And DP Poland Board Changes

UK EXECUTIVE CHANGE SUMMARY: Premier Oil And DP Poland Board Changes

7 Jan 21 16:02

Tiziana completes Covid-19 study in Brazil

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced the completion of its clinical study in Brazil on Monday, investigating nasally-administered Foralumab - its proprietary human monoclonal antibody - either alone or in combination with orally administered dexamethasone in Covid-19 patients.

4 Jan 21 15:19

LONDON MARKET MIDDAY: Vaccine Rollouts, M&A And Gold Surge Boost FTSE

LONDON MARKET MIDDAY: Vaccine Rollouts, M&A And Gold Surge Boost FTSE

4 Jan 21 12:16

Tiziana Announces Foralumab Trial Completion For Covid-19 Treatment

Tiziana Announces Foralumab Trial Completion For Covid-19 Treatment

4 Jan 21 12:15

UK WINNERS & LOSERS SUMMARY: Tui Rises As Tips "Normal" Summer Trading

UK WINNERS & LOSERS SUMMARY: Tui Rises As Tips "Normal" Summer Trading

4 Jan 21 10:44

UK TRADING UPDATE SUMMARY: Polar Capital Adds GBP1.2 Billion To Assets

UK TRADING UPDATE SUMMARY: Polar Capital Adds GBP1.2 Billion To Assets

17 Dec 20 19:37

UK DIRECTOR DEALINGS SUMMARY: IG Design CEO Sells GBP528,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: IG Design CEO Sells GBP528,000 In Shares

10 Dec 20 15:30

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

18 Nov 20 15:11

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.